Skip to main content
. 2021 Mar 5;5(5):1403–1411. doi: 10.1182/bloodadvances.2020002973

Figure 3.

Figure 3.

Kaplan-Meier estimated survival rates according to ELN molecular response categories. Overall survival of patients with CML receiving imatinib correlates strongly with the molecular response. Note that the observed failure curve did not reach a plateau.